Advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation.
1910 Genetics pioneers therapeutics discovery by integrating advanced AI, multimodal data, and high-throughput lab automation. The company provides an end-to-end AI platform and collaborative services to accelerate the design of small and large molecule drugs. It primarily serves pharmaceutical and biotechnology organizations, aiming to enhance R&D productivity and shorten drug development timelines.
$26.65M
5
| Customer | Success Story | Source |
|---|---|---|
| Collaborated with 1910 Genetics to help biopharma companies transform drug discovery by integrating Accenture’s AI expertise with 1910’s end‑to‑end AI platform. | ||
| 1910 Genetics applied its integrated AI drug discovery platform to identify and optimize novel lead compounds against a Genentech‑selected immuno‑oncology target. | ||
Nice Try Sign up to Ethos to access the full customer list Sign up to Ethos | Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. | Source |
Another Company | Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. | Source |
One More Company | Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sunt in culpa qui officia deserunt mollit anim id est laborum. | Source |
Nice Try | Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. | Source |
Sign up to Ethos to access the full customer list, plus detailed competitor and product analysis.
Sign up to Ethos